Buck M L, Wiest D, Gillette P C, Trippel D, Krull J, O'Neal W
Department of Clinical Pharmacy, Medical University of South Carolina, Charleston.
Clin Pharmacol Ther. 1989 Dec;46(6):629-33. doi: 10.1038/clpt.1989.198.
The pharmacokinetics and pharmacodynamics of intravenous atenolol were studied in 10 children during cardiac electrophysiologic studies. The intravenous pharmacokinetic data were best described by a two-compartment model and revealed the following (mean +/- SD): total body clearance, 0.15 +/- 0.06 L/hr/kg; volume of the central compartment 0.33 +/- 0.06 L/kg; volume of distribution at steady state, 0.83 +/- 0.15 L/kg; distributive elimination half-life, 0.29 +/- 0.08 hour; and terminal elimination half-life, 4.56 +/- 1.05 hours. The data suggest that children have a slightly shorter terminal elimination half-life than that of adults. Pharmacodynamic data showed a significantly (p less than 0.01) increased sinus cycle length and an increase in His to ventricle conduction time (p less than 0.05). Further studies are necessary to determine the optimal oral dose and dosing frequency of atenolol and to access the response of children to long-term treatment.
在心脏电生理研究期间，对10名儿童静脉注射阿替洛尔的药代动力学和药效学进行了研究。静脉给药的药代动力学数据用二室模型能得到最佳描述，结果如下（均值±标准差）：总体清除率，0.15±0.06升/小时/千克；中央室容积，0.33±0.06升/千克；稳态分布容积，0.83±0.15升/千克；分布消除半衰期，0.29±0.08小时；以及终末消除半衰期，4.56±1.05小时。数据表明儿童的终末消除半衰期比成人略短。药效学数据显示窦性周期长度显著增加（p<0.01），希氏束至心室传导时间增加（p<0.05）。有必要进一步研究以确定阿替洛尔的最佳口服剂量和给药频率，并评估儿童对长期治疗的反应。
